17,295 Shares in Haemonetics Corporation $HAE Acquired by Ieq Capital LLC

Ieq Capital LLC bought a new stake in shares of Haemonetics Corporation (NYSE:HAE) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 17,295 shares of the medical instruments supplier’s stock, valued at approximately $1,297,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HAE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Haemonetics by 3.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock worth $1,877,000 after buying an additional 971 shares during the period. Caxton Associates LLP bought a new stake in Haemonetics in the first quarter worth $216,000. United Services Automobile Association purchased a new position in Haemonetics during the 1st quarter valued at $212,000. Empowered Funds LLC grew its position in shares of Haemonetics by 9.1% during the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock worth $283,000 after buying an additional 372 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Haemonetics by 6.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after buying an additional 9,051 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Key Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Zacks raised its FY2027 EPS estimate to $5.27 from $5.20, increased Q4 2027 to $1.46 from $1.42, and lifted Q4 2028 to $1.46 from $1.41.
• Positive Sentiment: Longer-term projections also improved modestly: Q1 2029 EPS rose to $1.41 from $1.33, while FY2029 increased to $6.20 from $6.19. These changes suggest some confidence in Haemonetics’ longer-term earnings growth.
• Neutral Sentiment: The overall revision pattern is mixed, with increases in some later-period estimates offset by reductions in other quarters. Zacks’ FY2028 forecast is now $5.67, and its FY2027 estimate of $5.27 remains close to the $5.28 current-year consensus.
• Negative Sentiment: Zacks lowered several estimates, including Q2 2027 EPS to $1.30 from $1.32, Q3 2027 to $1.36 from $1.37, Q1 2028 to $1.27 from $1.31, Q2 2028 to $1.44 from $1.45, Q3 2028 to $1.50 from $1.52, and FY2028 to $5.67 from $5.69.

Analysts Set New Price Targets

HAE has been the subject of several recent research reports. Mizuho lifted their price target on Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Raymond James Financial reiterated an “outperform” rating and set a $105.00 price target on shares of Haemonetics in a report on Friday, August 7th. Barrington Research lifted their target price on shares of Haemonetics from $95.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, August 19th. Weiss Ratings upgraded Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen raised shares of Haemonetics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $97.56.

Haemonetics Stock Performance

Shares of HAE opened at $106.78 on Thursday. Haemonetics Corporation has a 52-week low of $47.31 and a 52-week high of $109.57. The firm has a market capitalization of $4.86 billion, a PE ratio of 52.34, a P/E/G ratio of 2.17 and a beta of 0.52. The firm has a 50-day moving average price of $83.68 and a 200 day moving average price of $69.40. The company has a quick ratio of 1.91, a current ratio of 3.08 and a debt-to-equity ratio of 1.40.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%.The company had revenue of $339.38 million during the quarter, compared to analyst estimates of $327.86 million. During the same quarter in the prior year, the company earned $1.10 earnings per share. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, sell-side analysts anticipate that Haemonetics Corporation will post 5.29 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.